| PHARVARIS N.V. EO -,12 |
| Niederlande |
| Gesundheit |
| NL00150005Y4 / A2QNWS |
| 9EN (Frankfurt) / PHVS (NASDAQ) |
| FRA:9EN, ETR:9EN, 9EN:GR, NASDAQ:PHVS |
| - |
| https://pharvaris.com/ |
|
Pharvaris N.V. is a biopharmaceutical company that specializes in discovering, developing, and commercializing innovative therapies to treat hereditary angioedema (HAE) and other bradykinin B2 receptor-mediated diseases. With its headquarters in Leid..
>Volltext.. |
| 2124.64 Mio. EUR |
| 1878.91 Mio. EUR |
| - |
| -174.2 Mio. EUR |
| -171.04 Mio. EUR |
| -2.78 EUR |
| 0.75 Mio. EUR |
| 249.3 Mio. EUR |
| -154.3 Mio. EUR |
| 10.77 |
| - |
| -11.68% |
| - |
| - |
| - |
| 5 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 4.793.735 Euro. |
| PHARVARIS |
| 02.07.26 |
|